Radioligand, Therapies

Radioligand Therapies Market to Show Immense Growth by 2034, Predicts DelveInsight | Key Companies - Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca

Published on 08/07/2025 at 18:05 | prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom


+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/radioligand-therapies-market-to-show-immense-growth-by-2034-predicts-delveinsight--key-companies---curium-us-eli-lilly-point-biopharma-fusion-astrazeneca-302191578.html

en | boerse | 67974065 |